https://european-biotechnology.net/wp-content/uploads/2026/01/roche-site-basel_official-web312708.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-10 07:25:082026-03-10 07:25:08Roche breast cancer drug falls short of expectations (for now)
https://european-biotechnology.net/wp-content/uploads/2026/03/thought-catalog-fnztlIb52gU-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 16:48:362026-03-09 16:48:36Roche and Zealand’s obesity contender clears phase 2, but investors were looking for more
https://european-biotechnology.net/wp-content/uploads/2026/03/curated-lifestyle-FXxBAw-gcGU-unsplash-1030x678-1.jpg6781030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 15:23:462026-03-09 15:23:46Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision
https://european-biotechnology.net/wp-content/uploads/2026/03/eb-20260309-mohamed-nohassi-Jthv-V45G0E-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 14:10:552026-03-09 16:32:03Servier buys Day One for $2.5bn to bolster its rare cancer pipeline
https://european-biotechnology.net/wp-content/uploads/2026/03/Team-picture-2-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-09 08:00:022026-03-09 08:00:02kyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performance
https://european-biotechnology.net/wp-content/uploads/2026/03/darpin-radio-image-web.png540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-06 07:11:162026-03-09 16:32:03Radioligands give Molecular Partners new momentum in a market already at full speed
https://european-biotechnology.net/wp-content/uploads/2026/03/amol-tyagi-zyJyB9S1oZs-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-04 08:45:512026-03-04 08:45:51Boehringer steps back from MASH programm as OSE restructure its pipeline
https://european-biotechnology.net/wp-content/uploads/2026/03/nvision-PHIP-Nagel-Luca-TUM.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-03 07:34:012026-03-03 07:34:01NVision visualizes metabolics at work and expands to the Cambridge Innovation Cluster
https://european-biotechnology.net/wp-content/uploads/2026/02/Sitryx-Lab-1_web960540.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-02-27 10:45:162026-02-27 10:45:16Sitryx adds another BigPharma and partners with Boehringer Ingelheim in autoimmune push
